Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
AquaBounty Technologies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
AquaBounty Technologies's earnings have been declining at an average annual rate of -26.1%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 47.7% per year.
Anahtar bilgiler
-26.1%
Kazanç büyüme oranı
10.0%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 47.7% |
Özkaynak getirisi | -73.8% |
Net Marj | -3,921.9% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
AquaBounty: Not Casting A Lure Yet
Aug 20AquaBounty Technologies GAAP EPS of -$0.08, revenue of $1.07M
Aug 09AquaBounty CEO Sylvia Wulf - Genetically Modified Sustainable Salmon
Mar 15AquaBounty Technologies' First Genetically Engineered Salmon On The Plate - Should You Join The Stream?
Jun 02Here's Why AquaBounty Technologies (NASDAQ:AQB) Can Manage Its Debt Despite Losing Money
May 09AquaBounty Technologies: Teach A Man To Fish And You Will Feed Him For A Lifetime
May 03What Kind Of Shareholders Hold The Majority In AquaBounty Technologies, Inc.'s (NASDAQ:AQB) Shares?
Feb 10Aquabounty Technologies launches stock offering; stock down ~5% after hours
Feb 03Richard Huber Is The Independent Non-Executive Director of AquaBounty Technologies, Inc. (NASDAQ:AQB) And They Just Picked Up 16% More Shares
Dec 20AquaBounty Technologies proposes public offering
Dec 09Gelir ve Gider Dağılımı
AquaBounty Technologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 2 | -76 | 13 | 1 |
31 Mar 24 | 3 | -32 | 13 | 1 |
31 Dec 23 | 2 | -28 | 14 | 1 |
30 Sep 23 | 2 | -25 | 12 | 1 |
30 Jun 23 | 2 | -25 | 12 | 1 |
31 Mar 23 | 3 | -24 | 12 | 1 |
31 Dec 22 | 3 | -22 | 11 | 1 |
30 Sep 22 | 3 | -22 | 11 | 1 |
30 Jun 22 | 3 | -24 | 11 | 2 |
31 Mar 22 | 2 | -23 | 11 | 2 |
31 Dec 21 | 1 | -22 | 10 | 2 |
30 Sep 21 | 1 | -22 | 10 | 2 |
30 Jun 21 | 0 | -19 | 9 | 2 |
31 Mar 21 | 0 | -17 | 8 | 2 |
31 Dec 20 | 0 | -16 | 7 | 2 |
30 Sep 20 | 0 | -14 | 7 | 2 |
30 Jun 20 | 0 | -13 | 7 | 2 |
31 Mar 20 | 0 | -14 | 8 | 2 |
31 Dec 19 | 0 | -13 | 7 | 2 |
30 Sep 19 | 0 | -14 | 4 | 3 |
30 Jun 19 | 0 | -14 | 5 | 3 |
31 Mar 19 | 0 | -13 | 4 | 3 |
31 Dec 18 | 0 | -12 | 4 | 3 |
30 Sep 18 | 0 | -11 | 7 | 4 |
30 Jun 18 | 0 | -10 | 7 | 4 |
31 Mar 18 | 0 | -10 | 6 | 4 |
31 Dec 17 | 0 | -9 | 5 | 3 |
30 Sep 17 | 0 | -9 | 6 | 3 |
30 Jun 17 | 0 | -9 | 5 | 3 |
31 Mar 17 | 0 | -9 | 5 | 3 |
31 Dec 16 | 0 | -8 | 5 | 3 |
30 Sep 16 | 0 | -8 | 4 | 4 |
30 Jun 16 | 0 | -7 | 3 | 4 |
31 Mar 16 | 0 | -7 | 4 | 4 |
31 Dec 15 | 0 | -7 | 4 | 3 |
30 Sep 15 | 0 | -7 | 4 | 3 |
30 Jun 15 | 0 | -7 | 5 | 3 |
31 Mar 15 | 0 | -7 | 5 | 3 |
31 Dec 14 | 0 | -7 | 4 | 3 |
30 Sep 14 | 0 | -7 | 5 | 2 |
30 Jun 14 | 0 | -6 | 4 | 2 |
31 Mar 14 | 0 | -5 | 3 | 2 |
Kaliteli Kazançlar: AQB is currently unprofitable.
Büyüyen Kar Marjı: AQB is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: AQB is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.
Büyüme Hızlandırma: Unable to compare AQB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: AQB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Özkaynak Getirisi
Yüksek ROE: AQB has a negative Return on Equity (-73.77%), as it is currently unprofitable.